The First Affiliated Hospital of Soochow University: all 258 studies

Page 3 of 3. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.

• Venetoclax Based Regimen for R/R T-ALLCompletedNCT05149378Phase 2
• Sitagliptin for Prevention of aGVHD After Alternative Donor TransplationCompletedNCT05149365Phase 3
• Avatrombopag to Promote Platelet Engraftment After Allo-HSCTStatus unknownNCT05143892Phase 2
• Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHDStatus unknownNCT05140616Phase 1/2
• Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction TherapiesStatus unknownNCT05123352
• A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MMStatus unknownNCT05088330Not applicable
• A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05066022Not applicable
• CD7 CAR T-cell for R/R CD7+ T Cell LymphomaStatus unknownNCT05059912Phase 2
• Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line TherapyStatus unknownNCT05039580Phase 4
• New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT05029141Phase 2
• The Effect of Precise Aerosol Inhalation Nursing on Sputum Excretion in Elderly Patients With Lung SurgeryStatus unknownNCT05025215Not applicable
• Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHDStatus unknownNCT05021276Phase 4
• Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream InfectionStatus unknownNCT05016752
• PBMC Collection for Production of UCAR T CellsStatus unknownNCT04963959Not applicable
• A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell LymphomaCompletedNCT04923789
• Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)Status unknownNCT04884984Phase 1/2
• Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.Status unknownNCT04882462Phase 2
• Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis PatientsStatus unknownNCT04875299
• Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With ALStatus unknownNCT04846439Phase 1/2
• Target Busulfan Exposure in Children With HSCT in ChinaStatus unknownNCT04786002
• Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute LeukemiaStatus unknownNCT04762485Phase 1/2
• Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk FeaturesStatus unknownNCT04752527Phase 2
• PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AMLStatus unknownNCT04722952Phase 3
• Abatacept s.c. for aGVHD Prevention in Haplo-HCTCompletedNCT04686929Phase 1/2
• Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMMStatus unknownNCT04677452Phase 1
• Effect of Bronchial Artery Protection on Cough After Thoracoscopic LobectomyCompletedNCT04651686Not applicable
• A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell LymphomaCompletedNCT04539444Phase 2
• Effectiveness of NextDose for Warfarin Dose IndividualizationStatus unknownNCT04510805Phase 4
• Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic LeukemiaStatus unknownNCT04446806Phase 4
• Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers PatientsStatus unknownNCT04446130Phase 3
• CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid LeukemiaStatus unknownNCT04351022Phase 1/2
• Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) PatientsStatus unknownNCT04287660Phase 3
• To Explore the Related Factors of Cough After Thoracoscopic PneumonectomyStatus unknownNCT04204148
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML PatientsStatus unknownNCT04087967Phase 3
• Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60Status unknownNCT04083911Phase 3
• CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03985007Phase 2
• CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic LeukemiaActive, not recruitingNCT03984968Phase 1/2
• CAR-T Cell Therapy Targeting to CD19 for R/R ALLActive, not recruitingNCT03919240Phase 1/2
• Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung CancerStatus unknownNCT03766490Not applicable
• Haplo HCT vs Haplo-cord HCT for Patients With AMLCompletedNCT03719534Phase 3
• Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCTStatus unknownNCT03715621
• 89Zr-KN035 PET Imaging in Patients With Advanced Solid TumorsStatus unknownNCT03638804Not applicable
• The Affection of Two Chest Management for Enhanced Recovery Program After Video-assisted Thoracoscopic Lobectomy.CompletedNCT03598296Not applicable
• Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCTActive, not recruitingNCT03455972Phase 1/2
• Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03437603Phase 2
• Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)Status unknownNCT03268889Not applicable
• Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCTStatus unknownNCT03256071Phase 2/3
• Risk Factors for Predictors of In-hospital Death in Acute Fulminant MyocarditisCompletedNCT03219996
• CAR-T for R/R B-NHLCompletedNCT03196830Phase 2
• PCD Versus RCD for the Treatment of Patients With Waldenstrom's MacroglobulinemiaStatus unknownNCT02971982Phase 1/2
• PDD vs PAD to Treat Initially Diagnosed MMStatus unknownNCT02577783Phase 4
• Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02323022Phase 3
• Hemostatic Complications in Hematopoietic Stem Cell TransplantationStatus unknownNCT02281240
• Sorafenib to Treat FLT3-ITD AMLStatus unknownNCT02156297
• Haplo-SCT vs ASCT With or Without Decitabine in AML CR1Status unknownNCT02059720Phase 3
• Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in ChinaStatus unknownNCT01812096Phase 1/2
• Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeStatus unknownNCT01809392Phase 2/3
• Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell TransplantationStatus unknownNCT01806116Phase 4

← The First Affiliated Hospital of Soochow University overview and focus areas